As overall market activity surged during the COVID-19 pandemic, investments into health technology (healthtech) grew significantly, according to Deloitte’s analysis of Pitchbook deal data. Over the past 18 months, however, investment volume has trended downward as investors weathered inflation, elevated interest rates, and greater uncertainty. In this environment, Deloitte has begun to see a shift in investor strategies and priorities. Rather than focusing narrowly on growth potential, some investors appear to be prioritizing proven business models that have a demonstrated track record of healthy liquidity and sustainable revenue and profit.
Read the full article: Some Healthtech Investors Are Shifting from Growth to Value //
Source: https://www2.deloitte.com/us/en/blog/health-care-blog/2024/some-healthtech-investors-are-shifting-from-growth-to-value.html